SCHEMBL3174990

SCHEMBL3174990

C=C(CC=CC(=O)O)C(=O)OC1CC2CCC1(C)C2(C)C

nearest known ligand 0.48

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.48
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.46
ELANE P08246 2/20 0.45
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
KMT2A Q03164 1/20 0.44
CYP19A1 P11511 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17728158 0.86 ALDH1A1 (0.46) CYP2C19ALDH1A1LMNAMAPTMAPK1
SCHEMBL3165671 0.83 CYP2C19 (0.52) CYP2C19ALDH1A1LMNAELANEMAPT
SCHEMBL3159498 0.82 CYP2C19 (0.45) CYP2C19ALDH1A1LMNAMAPTMAPK1
Styrene SCHEMBL16466837 0.82 CYP2C19 (0.51) CYP2C19ALDH1A1LMNAELANEMAPT
SCHEMBL29061732 0.81 ALDH1A1 (0.52) ALDH1A1LMNAMAPTMAPK1KMT2A
SCHEMBL1520947 0.81 ALDH1A1 (0.55) ALDH1A1LMNAMAPTMAPK1KMT2A
SCHEMBL26130563 0.81 ALDH1A1 (0.52) ALDH1A1LMNAMAPTMAPK1KMT2A
SCHEMBL824126 0.81 ALDH1A1 (0.52) ALDH1A1LMNAMAPTMAPK1KMT2A
SCHEMBL11027749 0.81 ALDH1A1 (0.52) ALDH1A1LMNAMAPTMAPK1KMT2A
SCHEMBL27450314 0.81 ALDH1A1 (0.52) ALDH1A1LMNAMAPTMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107427449-A For improving the composition and method of skin appearance 欧莱雅 2017-12-01 CN claimed
CN-105228701-B The device of liquid lip composition comprising inverted emulsion form and porous application component 莱雅公司 2019-10-25 CN disclosed
CN-110101606-A Liquid cosmetic composition 莱雅公司 2019-08-09 CN disclosed
WO-2019028248-A1 SYSTEMS AND METHODS FOR IMPROVING DELIVERY OF TOPICAL ACTIVES YOUNG PHARMACEUTICALS, INC. (US) 2019-02-07 WO disclosed
US-20100203004-A1 COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER L'OREAL (FR) 2010-08-12 US disclosed
EP-2205197-A1 COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER L'Oreal (FR) 2010-07-14 EP disclosed
US-20100009931-A1 ASSOCIATION OF A TENSOR AGENT OR DEVICE AND A SACCHARIDE COMPOUND L'OREAL (FR) 2010-01-14 US disclosed
US-20090285770-A1 Topical Compositions for Promoting Homeostasis of the Skin L'OREAL (FR) 2009-11-19 US disclosed
WO-2009056545-A1 COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER L'OREAL (FR) 2009-05-07 WO disclosed
US-20080305069-A1 Cosmetic Use of Tensing Agents to Improve the Thickness of the Skin and/or the Radiance of the Complexion L'OREAL (FR) 2008-12-11 US disclosed
EP-1951191-A1 TOPICAL COMPOSITIONS FOR PROMOTING HOMEOSTASIS OF THE SKIN L'Oréal (FR) 2008-08-06 EP disclosed
EP-1951378-A1 COSMETIC USE OF TENSING AGENTS TO IMPROVE THE THICKNESS OF THE SKIN AND/OR THE RADIANCE OF THE COMPLEXION L'Oréal (FR) 2008-08-06 EP disclosed
US-20080181953-A1 COMPOSITION CONTAINING A TENSIONING POLYMER AND HYBRID PARTICLES, METHODS OF USE L'OREAL (FR) 2008-07-31 US disclosed
US-20070166269-A1 Cosmetic composition containing a statistical polymer with a linear chain of ethylenic nature L'OREAL (FR) 2007-07-19 US disclosed
WO-2007057452-A1 COSMETIC USE OF TENSING AGENTS TO IMPROVE THE HOMEOSTASIS OF THE SKIN AND/OR THE RADIANCE OF THE COMPLEXION L'ORÉAL (FR) 2007-05-24 WO disclosed
WO-2007057448-A1 TOPICAL COMPOSITIONS FOR PROMOTING HOMEOSTASIS OF THE SKIN L'ORÉAL (FR) 2007-05-24 WO disclosed
WO-2007057451-A1 COSMETIC USE OF TENSING AGENTS TO IMPROVE THE THICKNESS OF THE SKIN AND/OR THE RADIANCE OF THE COMPLEXION L'ORÉAL (FR) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070166269-A1 Cosmetic composition containing a statistical polymer with a linear chain of ethylenic nature POLH, LAGE3, ELOVL6 CYP2C19 1081/4885ALDH1A1 3735/4885LMNA 239/4885
US-20080181953-A1 COMPOSITION CONTAINING A TENSIONING POLYMER AND HYBRID PARTICLES, METHODS OF USE CUTA, COL14A1, SOST CYP2C19 1641/4885ALDH1A1 4851/4885LMNA 376/4885
US-20090285770-A1 Topical Compositions for Promoting Homeostasis of the Skin CUTA, PIEZO1, TSLP CYP2C19 4822/4885ALDH1A1 3221/4885LMNA 2183/4885
US-20100009931-A1 ASSOCIATION OF A TENSOR AGENT OR DEVICE AND A SACCHARIDE COMPOUND PIEZO1, TRPA1, TREH CYP2C19 4531/4885ALDH1A1 1521/4885LMNA 3261/4885
US-20100203004-A1 COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER PHOSPHO1, CUTA, SGMS1 CYP2C19 3801/4885ALDH1A1 4031/4885LMNA 985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.